Skip to content
Peptilyze
CompoundsShopsCompareGuidesMethod
Metabolic research

Liraglutide studies

7,821 journal papers mention Liraglutide in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.

Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Liraglutide is safe, effective or approved for any use.

Compare Liraglutide prices, from €119.95 →

Papers
7,821
6,501 articles, 1,320 reviews
Earliest paper
1985
Most papers in 2025 (882)
Open access
59%
free to read somewhere
Reviews
17%
of all papers listed

What kind of studies

Of 5,713 papers in PubMed that mention Liraglutide in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.

  • Randomized controlled trials561
  • Other clinical trials55
  • Meta-analyses and systematic reviews415
  • Other reviews1,660
  • Case reports172
  • Animal studies only829
  • Studies in humans3,460

Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).

Registered clinical studies

Studies on ClinicalTrials.gov that mention Liraglutide in their intervention details. A registration says a study is planned or running, not what it found.

Registered
520
Completed
368
Ongoing or planned
47
Phase 1
72
Phase 2
79
Phase 3
113
  1. The Effect of Liraglutide on Body Weight, Body Composition, Ectopic Lipid Accumulation and Insulin Sensitivity in Subjects With Overweight or Obesity Without Diabetes

    NCT07913685CompletedPhase 4started 2023-04-05

  2. Changes in Body Composition Following Pharmacological Treatment for Obesity.

    NCT07908940Enrolling by invitationstarted 2025-09-01

  3. A Study on the Safety and Clinical Efficacy of Guominkang in the Treatment of Diabetic Kidney Disease

    NCT07907965Active, not recruitingPhase 2started 2025-10-20

  4. A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics

    NCT04466566CompletedPhase 3started 2022-10-17

  5. Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity

    NCT07901777Recruitingstarted 2026-09-15

The five most recently updated studies. See all 520 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.

Papers per year

1997 to 2026, peak 882 papers in a year. The latest year may still be incomplete.

1997: 0 papers1998: 0 papers1999: 0 papers2000: 2 papers2001: 2 papers2002: 0 papers2003: 5 papers2004: 12 papers2005: 12 papers2006: 12 papers2007: 28 papers2008: 49 papers2009: 86 papers2010: 134 papers2011: 159 papers2012: 202 papers2013: 221 papers2014: 294 papers2015: 360 papers2016: 413 papers2017: 441 papers2018: 495 papers2019: 513 papers2020: 505 papers2021: 467 papers2022: 449 papers2023: 543 papers2024: 693 papers2025: 882 papers2026: 835 papers19972026

Where it is published

  1. Diabetes328 papers
  2. Diabetes Obesity and Metabolism323 papers
  3. Diabetes Care106 papers
  4. Diabetes Therapy102 papers
  5. Value in Health90 papers

The papers

ShowAllOpen accessReviews

Most citedName in the title

  1. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

    Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2016

    Randomized trialOpen access7,631 citationsRead the open copy →

  2. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

    Xavier Pi-Sunyer, Arne Vernon Astrup, Ken Fujioka et al. · New England Journal of Medicine · 2015

    Randomized trialOpen access2,726 citationsRead the open copy →

  3. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

    Matthew James Armstrong, Piers Gaunt, Guruprasad Padur Aithal et al. · The Lancet · 2015

    Randomized trial · Phase 2Open access · CC BY2,205 citationsRead the open copy →

  4. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

    John B. Buse, Julio Rosenstock, Giorgio Sesti et al. · The Lancet · 2009

    Randomized trial1,504 citations

  5. Liraglutide and Renal Outcomes in Type 2 Diabetes

    Johannes F.E. Mann, David Dynnes Ørsted, Kirstine Brown‐Frandsen et al. · New England Journal of Medicine · 2017

    Randomized trialOpen access1,253 citationsRead the open copy →

  6. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes

    Melanie Jane Davies, Richard M. Bergenstal, Bruce W. Bode et al. · JAMA · 2015

    Randomized trialOpen access1,199 citationsRead the open copy →

  7. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

    Arne Vernon Astrup, Stephan Rössner, Luc Van Gaal et al. · The Lancet · 2009

    Randomized trial1,164 citations

  8. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

    Michael Albrecht Nauck, Anders H. Frid, Kjeld Hermansen et al. · Diabetes Care · 2008

    Randomized trialOpen access · CC BY-NC-ND1,129 citationsRead the open copy →

  9. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

    Alan J. Garber, Robert R. Henry, Robert E. Ratner et al. · The Lancet · 2008

    Randomized trial · Phase 31,058 citations

  10. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes

    Domenica M. Rubino, Frank L. Greenway, Usman Khalid et al. · JAMA · 2022

    Randomized trial · Phase 3Open access997 citationsRead the open copy →

  11. The Discovery and Development of Liraglutide and Semaglutide

    Lotte Bjerre Knudsen, Jesper F. Lau · Frontiers in Endocrinology · 2019

    ReviewOpen access · CC BY971 citationsRead the open copy →

  12. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

    Anna Secher, Jacob Jelsing, Arian F. Baquero et al. · Journal of Clinical Investigation · 2014

    Animal studyOpen access962 citationsRead the open copy →

  13. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

    Carel Wynand le Roux, Arne Astrup, Ken Fujioka et al. · The Lancet · 2017

    Randomized trial850 citations

  14. Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

    Bernard Zinman, John E. Gerich, John B. Buse et al. · Diabetes Care · 2009

    Randomized trialOpen access · CC BY-NC-ND848 citationsRead the open copy →

  15. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

    on behalf of the NN8022-1923 Investigators, Thomas A. Wadden, Priscilla A. Hollander et al. · International Journal of Obesity · 2013

    Randomized trial842 citations

  16. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

    on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, David L Russell-Jones, Allan Arthur Vaag et al. · Diabetologia · 2009

    Randomized trialOpen access · CC BY-NC837 citationsRead the open copy →

  17. Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)

    Michel Marre, Jonathan E. Shaw, Michael Brändle et al. · Diabetic Medicine · 2009

    Randomized trialOpen access · CC BY823 citationsRead the open copy →

  18. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

    Patrick Mahlen O'Neil, Andreas L. Birkenfeld, Barbara M. McGowan et al. · The Lancet · 2018

    Randomized trial · Phase 2814 citations

  19. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

    on behalf of the NN8022-1807 Investigators, Arne Vernon Astrup, Raffaele Carraro et al. · International Journal of Obesity · 2011

    Randomized trialOpen access · CC BY-NC-ND757 citationsRead the open copy →

  20. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity

    Aaron S. Kelly, Pernille Auerbach, Margarita Barrientos Pérez et al. · New England Journal of Medicine · 2020

    Randomized trial · Phase 3Open access724 citationsRead the open copy →

  21. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction

    Kenneth B. Margulies, Adrian F. Hernandez, Margaret M. Redfield et al. · JAMA · 2016

    Randomized trial · Phase 2Open access706 citationsRead the open copy →

  22. The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

    Paula L. McClean, Vadivel Parthsarathy, Émilie Faivre et al. · Journal of Neuroscience · 2011

    Study in humansOpen access · CC BY-NC-SA698 citationsRead the open copy →

  23. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial

    Richard E. Pratley, Aslam Amod, Soren Tetens Hoff et al. · The Lancet · 2019

    Randomized trial · Phase 3595 citations

  24. Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial

    Anders Jorsal, Caroline Kistorp, Pernille Holmager et al. · European Journal of Heart Failure · 2016

    Randomized trialOpen access592 citationsRead the open copy →

  25. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

    Richard E. Pratley, Michael Albrecht Nauck, Timothy Silleck Bailey et al. · The Lancet · 2010

    Randomized trial587 citations

  26. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial

    on behalf of the SCALE study group, Adam Blackman, Gary D. Foster et al. · International Journal of Obesity · 2016

    Randomized trialOpen access · CC BY-NC-ND584 citationsRead the open copy →

  27. GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

    Mohammad Hossein Noyan-Ashraf, M. Abdul Momen, Kiwon Ban et al. · Diabetes · 2009

    Study in humansOpen access · CC BY-NC-ND577 citationsRead the open copy →

  28. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

    John B. Buse, Michael Albrecht Nauck, Thomas M. Forst et al. · The Lancet · 2012

    Randomized trial565 citations

  29. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

    J van Can, Birgitte Sloth, Camilla Bjørn Jensen et al. · International Journal of Obesity · 2013

    Randomized trialOpen access · CC BY-NC-ND537 citationsRead the open copy →

  30. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

    Julie Rehné Lundgren, Charlotte Janus, Simon Birk Kjær Jensen et al. · New England Journal of Medicine · 2021

    Randomized trialOpen access536 citationsRead the open copy →

  31. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways

    Günaj Rakipovski, Bidda Charlotte Rolin, Jane Nøhr et al. · JACC Basic to Translational Science · 2018

    Open access · CC BY-NC-ND509 citationsRead the open copy →

  32. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

    Kerry Hunter, Christian Hölscher · BMC Neuroscience · 2012

    Animal studyOpen access · CC BY504 citationsRead the open copy →

  33. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

    Kathleen Marie Dungan, Santiago Tofé, Thomas M. Forst et al. · The Lancet · 2014

    Randomized trial · Phase 3487 citations

  34. Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

    Tina Vilsbøll, Milan Zdravkovic, T Le-Thi et al. · Diabetes Care · 2007

    Randomized trialOpen access467 citationsRead the open copy →

  35. One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes

    Kristine Degn, Claus Bogh Juhl, Jeppe Sturis et al. · Diabetes · 2004

    Randomized trialOpen access427 citationsRead the open copy →

  36. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)

    Matthew Capehorn, Andrei‐Mircea Catarig, Julie Kjærulff Furberg et al. · Diabetes & Metabolism · 2019

    Randomized trial · Phase 3412 citations

  37. Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect

    Stephanie R. Sisley, Ruth Gutiérrez‐Aguilar, Michael M. Scott et al. · Journal of Clinical Investigation · 2014

    Animal studyOpen access399 citationsRead the open copy →

  38. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

    Stephen C. L. Gough, Bruce W. Bode, Vincent C. Woo et al. · The Lancet Diabetes & Endocrinology · 2014

    Randomized trial · Phase 3368 citations

  39. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease

    Paula L. McClean, Christian Hölscher · Neuropharmacology · 2013

    Animal study361 citations

  40. Liraglutide in Children and Adolescents with Type 2 Diabetes

    William V. Tamborlane, Margarita Barrientos Pérez, Udi Fainberg et al. · New England Journal of Medicine · 2019

    Randomized trialOpen access360 citationsRead the open copy →

LatestName in title or abstract

  1. GLP-1 Receptor Agonists Versus Empagliflozin or Dapagliflozin in the MASLD-Heart Failure Phenotype: An Exploratory Propensity-Matched Cohort Study

    Naveen Gautam, Tien Manh Huynh, Hong Hieu Truong et al. · Balkan Medical Journal · 2026

    Open access · CC BY-NC-NDRead the open copy →

  2. Potential synergy between GLP-1 receptor agonists and follicle-stimulating hormone in improving spermatogenesis: biological rationale and future directions

    Sandro La Vignera, Aldo Eugenio Calogero, Rossella Cannarella et al. · Frontiers in Endocrinology · 2026

    Open access · CC BYRead the open copy →

  3. Development of an albumin-binding domain-fused GLP-1 analog: Structural insights, receptor activation, and functional characterization

    Mohammad Reza Abolhassan, Zamara Mariam, Arpita Prasad et al. · International Journal of Biological Macromolecules · 2026

  4. The Liraglutide Effects in Atrial Fibrillation (LEAF) Biomarker Study

    Gianluca Iacobellis, Raul David Mitrani, Armando J. Mendez et al. · JACC Advances · 2026

    Open access · CC BY-NC-NDRead the open copy →

  5. The pharmacological frontier in obstructive sleep apnoea: From pathophysiologic endotypes to precision medicine

    Hemant Kumar, Anurag Tripathi, Sulakshana Gautam et al. · Lung India · 2026

    Open access · CC BY-NC-NDRead the open copy →

  6. Liraglutide in type 1 diabetes: Cardiometabolic benefits and vascular risk assessment

    Hong Zhou, Guobin Miao · Diabetic Medicine · 2026

    Open accessRead the open copy →

  7. Efficacy and tolerability of liraglutide for refractory bile acid diarrhoea

    Angelina Cham, Dan Greer, Mais Khasawneh et al. · Frontline Gastroenterology · 2026

  8. Glucagon-Like Peptide-1 Analog–Type Amyloidosis: A Case Report and Review of the Literature

    John Loggie, Robert C. McKay, Samih H. Nasr et al. · American Journal of Dermatopathology · 2026

  9. EMERGING PHARMACOLOGICAL STRATEGIES IN OBESITY: FROM GLP-1 AGONISTS THROUGH TRIPLE INCRETIN THERAPY TO AMYLIN ANALOGS – NARRATIVE REVIEW

    Dagmara Laufer, Olga Klimczak, Filip Chodań et al. · Archiv Euromedica · 2026

    ReviewOpen accessRead the open copy →

  10. Changes in Sexual Function and Sexual Quality of Life During GLP-1–Based Therapy in Premenopausal Women with Obesity

    Hazel Demiröz Öztürk, Yusuf Öztürk · Medicina · 2026

    Open access · CC BYRead the open copy →

  11. Case Report: KBG syndrome in an adult presenting with diabetes, gout, and hypogonadism

    Wei Shi, Zhuhuan Xie, Chenrui Liu et al. · Frontiers in Endocrinology · 2026

    Open access · CC BYRead the open copy →

  12. GLP‐1 receptor activation attenuates chronic migraine‐like behaviour: Sex‐specific modulation of opioid‐ and endocannabinoid‐related pathways

    Katarina Sićović, Katarina Nastić, Miroslav Dinić et al. · British Journal of Pharmacology · 2026

    Open access · CC BYRead the open copy →

  13. AI-enabled drug repurposing in Alzheimer’s disease: from computational nomination to pharmacological proof

    Xinzhong Li, Illana Gozes · Frontiers in Pharmacology · 2026

    Open access · CC BYRead the open copy →

  14. Enteric-Coated Metformin Tablets: In vitro Release and Metabolic Outcomes in High Fat Diet Fed Rats

    Bushra Mohammed Yaseen, Musab Mohammed Khalaf, Myasar Mohammed Alkotaji · Journal of Pharmaceutical Innovation · 2026

  15. Systematic review of the neuroprotective potential of GLP1 receptor agonists and SGLT2 inhibitors in Alzheimer’s disease and cognitive impairment

    Marwa A. Dewer, Salma G. Dawod, Nada M. Elbadawy et al. · Discover Neuroscience · 2026

    ReviewOpen access · CC BYRead the open copy →

  16. Oral Health–Related Adverse Events of GLP-1 Receptor Agonists

    F.C. Massarotto, A.H. Mahmoud, G.E. Watson et al. · JDR Clinical & Translational Research · 2026

    Open accessRead the open copy →

  17. Glucagon-like Peptide-1 Receptor Agonists in Heart Transplant Recipients With Type 2 Diabetes: A Multicenter Study

    Zorba Blázquez‐Bermejo, Daniel Enríquez-Vázquez, Elena García‐Romero et al. · Transplantation · 2026

  18. Target Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis

    Dustin Le, Evan Forman, Walter K. Kraft et al. · Diabetes Care · 2026

  19. GLP‐1–Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection

    Thales Rossatto, Ricardo de Andrade Oliveira, Andréia Machado Cardoso · Diabetes Obesity and Metabolism · 2026

    ReviewOpen access · CC BYRead the open copy →

  20. Genetic GHSR deficiency and LEAP2 treatment enhance the glucose-lowering effects of liraglutide in male mice in a metabolic state-dependent manner

    Daniela Cassano, Gimena Fernández, María Paula Cornejo et al. · Life Sciences · 2026

    Open access · CC BYRead the open copy →

  21. Liraglutide regulate osteogenesis-resorption via macrophage under compressive stress

    Runze Kong, Difei Wu, Xiaochen Men et al. · Frontiers in Pharmacology · 2026

    Open access · CC BYRead the open copy →

  22. Body Composition and Quality of Weight Loss During Liraglutide 3.0 mg Therapy: Association with a Structured Exercise Programme

    Marija V. Macesic, Filip Radovic, Janko Zeković et al. · Sports · 2026

    Open access · CC BYRead the open copy →

  23. Efficacy and safety of GLP-1 receptor agonists for antipsychotic-related overweight and metabolic dysregulation: a systematic review and meta-analysis

    Lingyan Zhou, Ying Zhang, Chao Shen et al. · European Journal of Clinical Pharmacology · 2026

    Meta-analysis

  24. Clinical course and tolerability of glucagon-like peptide-1 receptor agonists in ocular inflammatory disease

    Aubrey Nguyen, Negin Yavari, Osama Elaraby et al. · Journal of Ophthalmic Inflammation and Infection · 2026

    Open access · CC BYRead the open copy →

  25. Intranasal Delivery of Engineered Neural Stem Cell-Derived Extracellular Vesicles Enables Targeted Delivery of Liraglutide to the Brain

    S Mehta, Suresh Thangudu, Golnaz Haghverdi et al. · ACS Nano Medicine · 2026

  26. Skeletal effects of GLP-1 receptor agonist therapy in adults with overweight or obesity: a systematic review

    Cheng-Hao Lai, YU-TZU LI, Ting-Shuan Wu et al. · Archives of Osteoporosis · 2026

    Systematic review

  27. GLP-1 RECEPTOR AGONISTS IN OBESITY MANAGEMENT: EFFICACY, TOLERABILITY AND SUPPLY CHALLENGES

    Eleni Antoniou, Rhys Trevithick, Lotte Kuipers · Pharma research · 2026

    Open access · CC BYRead the open copy →

  28. How Well Are We Measuring Nausea? A Narrative Review of Patient‐Reported Outcome Gaps in GLP ‐1 Receptor Agonist Obesity Trials

    Lima Oria, Mohammad Darkhabani · Diabetes Obesity and Metabolism · 2026

    Review

  29. GLP-1 Receptor Agonists as Neuroprotective Agents in Alzheimer’s Disease: Mechanisms and Therapeutic Potential

    Mahnoor Nadeem · Carleton undergraduate journal of science. · 2026

    Open access · CC BY-NC-NDRead the open copy →

  30. Emerging Therapeutic Strategies for Child and Adolescent Obesity: A Narrative Review

    Tomaso Oliaro, Amianto Federico · Nutrients · 2026

    ReviewOpen access · CC BYRead the open copy →

  31. Obesity in Children Aged 2 to 12 Years

    Claudia K. Fox, Sarah Armstrong, Aaron S. Kelly · JAMA · 2026

  32. Bariatric surgery compared with GLP-1 receptor agonists: durability of weight loss and control of comorbidities

    Karoline Sabatine Volpato, Rafael Berger Simionato, Rafaela Cristina Colorado Borges Farias et al. · International Health Sciences Review · 2026

    Open access · CC BYRead the open copy →

  33. Availability of age-stratified evidence for GLP1 receptor agonists and SGLT2 inhibitors: an analysis of European public assessment reports with a focus on older patients

    Svea Stüdemann, Maik Gollasch, Stefan Engeli · Frontiers in Pharmacology · 2026

    Open access · CC BYRead the open copy →

  34. Exploring heterogeneous treatment effects for GLP-1 receptor agonists in patients with type 2 diabetes

    Luke Keele, Matteo Bonvini, Andrea Marheim Storås et al. · American Journal of Epidemiology · 2026

  35. Investigating the Effects of GLP-1 Agonist (Liraglutide) Treatment on Weight Loss and Metabolic Markers in Obese Kidney Transplant Recipients

    Nooshin Amadi, Houra Akbari, Mohsen Nafar et al. · Iranian Journal of Kidney Diseases · 2026

    Open accessRead the open copy →

  36. Effect of GLP-1RA on circulating SASP levels and wound healing in patients with diabetic foot ulcers: a randomized, placebo-controlled clinical trial

    Murong Li, Cuili Yan, LI Jiangxia et al. · Diabetology & Metabolic Syndrome · 2026

    Open access · CC BY-NC-NDRead the open copy →

  37. Epicardial Versus Circulating Adiponectin: An Unresolved Distinction in Liraglutide‘s Anti-Arrhythmic Mechanism

    Miao Miao, Zhikui Chen · Cardiovascular Drugs and Therapy · 2026

  38. GLP-1 receptor agonist therapy and incident atrial fibrillation in non-diabetic adults with obesity and chronic kidney disease: a propensity matched cohort study

    Abdulraheem Hassan, Efeturi Okorigba, Chilaka Grace et al. · International Journal of Cardiology · 2026

  39. INCRETIN-BASED THERAPIES AND DEMENTIA: RECONCILING EPIDEMIOLOGICAL PREVENTION SIGNALS WITH NEGATIVE DISEASE-MODIFYING TRIALS IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE

    Joao Fernandes Floriano, María Elizabeth Menezes · Revista Multidisciplinar do Nordeste Mineiro · 2026

    Open access · CC BYRead the open copy →

  40. Impact of Metabolic Syndrome, Type 2 Diabetes Mellitus, and Metabolic Pharmacotherapies on the Progression of MASLD/MASH to Advanced Fibrosis and Cirrhosis: A Systematic Review

    Isabela Bullara Mirandola, ANA THAIS PIRES ALVES, Damaris Fonseca Peixoto Silva et al. · Archives of Gastroenterology Research · 2026

    ReviewOpen accessRead the open copy →

Each list shows up to 40 papers.See all 7,821 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:31 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.